An ongoing dialogue on HIV/AIDS, infectious diseases,
December 20th, 2014
New HCV Option Effective, Safe, Well-Tolerated — And Use Will Likely Be Driven by Payors
As expected, the FDA approved the next treatment option for HCV on Friday — “Viekira Pak”, a (sometimes complete) regimen consisting of ritonavir-booted parataprevir and ombitasvir given as a two pills once a day, plus one pill of of dasabuvir given twice daily. It is indicated for treatment of HCV genotype 1. For those of you mechanistically inclined, parataprevir […]
April 12th, 2014
Unwittingly, HCV “News” Brackets Our Current Treatment Era on Successive Days
I’ve already told you what a fan I am of Physician’s First Watch, the daily email summary of hot medical news provided by my colleagues here at the Massachusetts Medical Society. If you haven’t signed up, you must do so — let’s play a short tune (always a favorite) for background music while you head over […]